Global CAR T-Cell Immunotherapy Market Growth (Status and Outlook) 2025-2031

According to this study, the global CAR T-Cell Immunotherapy market size will reach US$ million by 2031.

CAR T-Cell Immunotherapy is a new type of cancer treatment. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy. T cells is a type of white blood cell extracted from the patient’s blood by doctors, and added an artificial receptor to their surface. When infused into a patient, the cells get multiplied and stay in the body as “living drugs” and help in detecting and fighting cancer. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.

United States market for CAR T-Cell Immunotherapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for CAR T-Cell Immunotherapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for CAR T-Cell Immunotherapy is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key CAR T-Cell Immunotherapy players cover AbbVie, Celgene, Kite Pharma, Oxford BioMedica, Novartis, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “CAR T-Cell Immunotherapy Industry Forecast” looks at past sales and reviews total world CAR T-Cell Immunotherapy sales in 2024, providing a comprehensive analysis by region and market sector of projected CAR T-Cell Immunotherapy sales for 2025 through 2031. With CAR T-Cell Immunotherapy sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world CAR T-Cell Immunotherapy industry.

This Insight Report provides a comprehensive analysis of the global CAR T-Cell Immunotherapy landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on CAR T-Cell Immunotherapy portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global CAR T-Cell Immunotherapy market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for CAR T-Cell Immunotherapy and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global CAR T-Cell Immunotherapy.

This report presents a comprehensive overview, market shares, and growth opportunities of CAR T-Cell Immunotherapy market by product type, application, key players and key regions and countries.

Segmentation by Type:
Monotherapy
Combination Therapy

Segmentation by Application:
Hematologic Malignancies
Solid Malignancies

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Celgene
Kite Pharma
Oxford BioMedica
Novartis
Gilead
Pfizer
Cellectis
Bellicum
Mustang Bio
CARsgen Therapeutics
Xyphos
Minerva Biotechnologies
Adaptimmune
Ziopharm Oncology
Aurora Biopharma
Creative Biolabs

Please note: The report will take approximately 2 business days to prepare and deliver. Show more